Clinical evaluation of sizofiran combined with irradiation in patients with cervical cancer. A randomized controlled study; a five-year survival rate.
Following a previous report we ascertained the effectiveness of sizofiran (Schizophyllan:SPG) to prolong the survival and time to recurrence of the patients with Stage II or III cervical cancer, as evaluated in a 5-year randomized controlled study conducted in 19 institutions in Japan. Of the overall patients with Stage II or III cancer, time to recurrence and survival rate in the group on SPG were significantly longer than in the control group. In the Stage II patients, there was significant difference in time to recurrence, and survival of SPG group tended to be longer than that of the control group. However, in the Stage III patients, there was no significant difference in either time to recurrence or survival rate.
Okamura
K
K
Department of Obstetrics and Gynecology, Tohoku University, School of Medicine, Sendai, Japan.
Suzuki
M
M
Chihara
T
T
Fujiwara
A
A
Fukuda
T
T
Goto
S
S
Ichinohe
K
K
Jimi
S
S
Kasamatsu
T
T
Kawai
N
N
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006025:Glycosaminoglycans / Q000627:therapeutic use*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012566:Sizofiran / Q000627:therapeutic use*; D015996:Survival Rate; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy
D000970:Antineoplastic Agents; D006025:Glycosaminoglycans; D012566:Sizofiran